Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis

CompletedOBSERVATIONAL
Enrollment

125

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

December 31, 2019

Conditions
Exocrine Pancreatic Insufficiency
Interventions
DIAGNOSTIC_TEST

Labeled triolein urea breath test

"The diagnosis of EPI will be made through the combination of two diagnostic tests.~The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.~The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."

Trial Locations (1)

28208

Parc Tauli Hospital, Barcelona

Sponsors
All Listed Sponsors
lead

Corporacion Parc Tauli

OTHER

NCT03236038 - Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis | Biotech Hunter | Biotech Hunter